| Trial ID: | L3255 |
| Source ID: | NCT00687063
|
| Associated Drug: |
Insulin Detemir
|
| Title: |
Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes
|
| Acronym: |
DIABESITY
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin detemir
|
| Outcome Measures: |
Primary: Weight change from baseline, after 26 weeks | Secondary: Number of serious adverse events, after 26 weeks|Number of all adverse events, after 26 weeks|Number of all hypoglycemic episodes (24 hr, daytime and nocturnal), after 26 weeks|HbA1c change from baseline, after 26 weeks|FBG (Fasting Blood Glucose) change from baseline, after 26 weeks|Percentage of patients achieving targets of HbA1c less than 7 % and less than 6.5 %, after 26 weeks|Insulin dose and frequency at the end of the study, after 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
10008
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-04
|
| Completion Date: |
2009-02
|
| Results First Posted: |
|
| Last Update Posted: |
2023-11-02
|
| Locations: |
Bangalore, 560001, India
|
| URL: |
https://clinicaltrials.gov/show/NCT00687063
|
